16 production sites on 5 continents.
Affiliates or offices in 79 countries.
Products marketed in more than 170 countries.
Approximately 43,100 employees (FTEs June 2018).
19% within research and development
32% in production and production administration
37% in international sales and marketing
12% in administration
Affiliate distribution (FTEs)
Approximately 40% of employees are located in Denmark (17,294 FTEs) and 60% in the rest of the world:
Africa, Asia, Middle East & Oceania: 7,050
Europe (excl. HQ): 4,479
Japan (1,146) & Korea: 1,287
Latin America: 1,947
North America (US 6,129 & Canada 295): 6,424
(includes all Novo Nordisk and NNE employees in the respective locations)
54,337 million Danish kroner
Sales by business segment
Diabetes and obesity care total:
45,641 million Danish kroner
8,696 million Danish kroner
Sales by region
North America Operations:
26,955 million Danish kroner
USA: 25,830 million Danish kroner
27,382 million Danish kroner
Region Europe: 10,693 million Danish kroner
Region AAMEO: 6,093 million Danish kroner
Region China: 5,780 million Danish kroner
Region Japan & Korea: 2,741 million Danish kroner
Region Latin America: 2,075 million Danish kroner
Novo Nordisk A/S
CVR nr. 24 25 67 90